It is of note that most research on the influence of thyroid hormone replacement therapy on tumor progression has been conducted in patients who developed hypothyroidism under cancer-specific therapy, and to the best of the authors’ knowledge none has yet been conducted in gastroesophageal cancer. The gene discussed is TG; the disease is hypothyroidism.